Superior cartilage repair with BST-CarGel added to conventional microfracture treatment .
This report has been verified
by one or more authors of the
original publication.
Este estudo foi identificado como tendo um impacto potencialmente elevado.
A métrica de Alto Impacto da OE, baseada em IA, estima a influência que um artigo poderá ter, integrando sinais da revista em que foi publicado e do conteúdo científico do próprio artigo.
Desenvolvido com recurso ao mais avançado processamento de linguagem natural, o modelo High Impact da OE prevê com maior precisão o desempenho futuro de um estudo em termos de citações do que o fator de impacto da revista por si só.
Isto permite o reconhecimento precoce de investigação clinicamente significativa e ajuda os leitores a concentrarem-se nos artigos com maior probabilidade de moldar a prática futura.
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2013;1(20):4 J Bone Joint Surg Am. 2013 Sep 18;95(18):1640-50Eighty patients aged 18 to 55 years, with a single focal cartilage lesion on the femoral condyles and moderate knee pain, were randomized to evaluate the efficacy of BST-CarGel (Piramal Life Sciences, Bio-Orthopaedic Division) treatment in addition to conventional microfracture treatment and physiotherapy over 12 weeks. Patients were primarily assessed for repair tissue quantity and quality evaluated at 12 months by quantitative 3D MRI. The evidence presented in this study demonstrated that BST-CarGel (Piramal Life Sciences, Bio-Orthopaedic Division) treatment resulted in superior cartilage tissue, increased quantity, and improved structural characteristics when compared to microfracture treatment alone. Secondary clinical outcomes (WOMAC and SF-36) were comparable between groups, along with similar safety outcomes.
Was the allocation sequence adequately generated?
Was allocation adequately concealed?
Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?
Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?
Blinding Patients: Was knowledge of the allocated interventions adequately prevented?
Was loss to follow-up (missing outcome data) infrequent?
Are reports of the study free of suggestion of selective outcome reporting?
Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?
Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?
Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?
Sim = 1
Incerto = 0,5
Não relevante = 0
Não = 0
A Avaliação dos Critérios de Relato avalia a transparência com que os autores relatam as caraterísticas metodológicas e do ensaio na publicação. A avaliação está dividida em cinco categorias que são apresentadas de seguida.
3/4
Randomization
4/4
Outcome Measurements
4/4
Inclusion / Exclusion
4/4
Therapy Description
4/4
Statistics
Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65
O Índice de Fragilidade é uma ferramenta que auxilia na interpretação de achados significativos, fornecendo uma medida de força para um resultado. O Índice de Fragilidade representa o número de eventos consecutivos que precisam de ser adicionados a um resultado dicotómico para que o resultado deixe de ser significativo. Um número pequeno representa um resultado mais fraco e um número grande representa um resultado mais forte.
Porque é que este estudo era necessário agora?
Microfracture is the current standard of care for articular cartilage damage and although this treatment has demonstrated success, the procedure may result in poor tissue quality and highly variable outcomes due to the instability of the marrow-derived blood clots formed in the lesion. BST-CarGel (Piramal Life Sciences, Bio-Orthopaedic Division) was developed to stabilize the blood clot in the cartilage lesion by dispersing a soluble polymer scaffold containing chitosan (a crustacean exoskeleton glucosamine polysaccharide with desirable biomaterial properties) throughout the blood. The current evidence examining optimal interventions for articular cartilage damage suffers from low methodological quality, and this study was therefore needed to evaluate the efficacy of additional BST-CarGel in the treatment of symptomatic cartilage lesions of the femoral condyle with microfracture.
Qual era a principal questão de investigação?
Does BST-CarGel paired with microfracture treatment for symptomatic cartilage lesions of the femoral condyle result in superior repair cartilage quantity and quality compared to microfracture treatment alone, evaluated over 12 months?
- Baseline post-debridement lesion areas and volumes were each numerically greater for the BST-CarGel group (largest lesion: 6.77cm squared) compared to the microfracture group (largest lesion: to 4.46cm squared) (2.34 +/- 1.43 compared to 1.95 +/- 1.3cm squared; p= 0.20 and 0.95 +/- 0.82 vs. 0.70 +/- 0.53cm cubed; p= 0.12 respectively).
- At 12 months, lesions treated with BST-CarGel were filled with significantly more repair tissue (92.8% +/- 2.0%) compared to the microfracture group lesions (85.2% +/- 2.1%) (p= 0.011). BST-CarGel additionally resulted in more consistent outcomes in terms of producing a greater degree of filling.
- At 12 months, BST-CarGel treatment resulted in significantly lower (p= 0.033) adjusted T2 relaxation times (70.5 +/- 4.5ms) compared to the microfracture group (85.0 +/- 4.9ms). Note that a lower T2 relaxation time indicated an improved level of tissue quality.
- No significant differences between groups was observed for any WOMAC subscales at 12 months (all p> 0.05) and both treatments showed significant improvement from baseline in all 3 subscales (p< 0.0001).
- SF-36 scores revealed no significant differences between groups for any subscales (p> 0.05 for all), however the single-question Reported Health Transition item indicated that 75% BST-CarGel patients reported feeling “better than one year ago” compared to 60% in the microfracture group (p= 0.22).
- Reports of adverse events were similar between the BST-CarGel group (97.6%; 40 patients) compared to the microfracture group (92.3%; 36 patients). Most adverse events were of mild to moderate intensity with arthralgia being the most frequent (68.3% in the BST-CarGel group and 64.1% in the microfracture group).
- Procedure related adverse events were exhibited in 38 (92.6%) BST-CarGel group patients compared to 30 (76.2%) microfracture group patients. The BST-CarGel Group reported 5 patients (12.2%) with unanticipated device-related adverse events and 4 (9.8%) anticipated device-related adverse events that were mild to moderate in intensity. Three severe cascading unanticipated device-related adverse events occurred in a single patient.
De que é que me devo lembrar mais?
At 12 months, BST-CarGel (Piramal Life Sciences, Bio-Orthopaedic Division) treatment resulted in superior cartilage tissue, increased quantity, and improved structural characteristics when compared to microfracture treatment alone. Secondary clinical outcomes were comparable between groups, along with similar safety outcomes.
Como é que isto afectará o tratamento dos meus doentes?
The evidence presented in this study suggested that BST-CarGel (Piramal Life Sciences, Bio-Orthopaedic Division) treatment may be an effective addition to the treatment of symptomatic cartilage lesions of the femoral condyle. It is important to note that the findings of this study are limited by the relatively short follow-up period. Further study that examines long-term clinical benefit is warranted.
AVISO LEGAL
O conteúdo desta página destina-se apenas a fins informativos e não pretende substituir o aconselhamento, diagnóstico ou tratamento médico profissional. Se necessitar de tratamento médico, procure sempre o conselho do seu médico ou dirija-se ao serviço de urgência mais próximo. As opiniões, crenças e pontos de vista expressos pelos indivíduos no conteúdo encontrado nesta página não reflectem as opiniões, crenças e pontos de vista da OrthoEvidence.
0 de 4 artigos mensais GRATUITOS desbloqueados
